Fusion Pharmaceuticals Inc., a Hamilton, Ontario-based clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio […]
Bay Area Health Trust (bayareahealthtrust.com), is a Hamilton based company that operates businesses in the life sciences and seeks strategic opportunities in new technologies in the health and life science fields. VoxNeuro (voxneuro.com) has been dubbed as one of Hamilton’s “startups to watch” from leaders across the industry. For Bay Area Health Trust, whose goal […]
A Hamilton Health Sciences team has developed an innovative smartphone application that will soon help patients manage the effects of concussions on their daily lives. The MyHeadHealth mobile app will provide concussion patients with a personalized treatment plan, instructional videos, educational tools and a way for them to input information on their health and symptoms. […]
Sep-2020
Bay Area Health Trust (www.bayareahealthtrust.com), a Hamilton, Ontario based company today announced an exclusive licensing agreement for the ‘McMaster Molecular Medium (“MMM”) with McMaster University. Developed by researchers from St. Joseph’s Healthcare Hamilton‘s Disease Diagnostics and Development Group, MMM will enable labs to safely increase their COVID testing capacity and therefore return results faster. In […]
Sep-2020
n the hopes of averting future pandemics, Hamilton’s McMaster University is connecting a number of its top infectious disease clinicians and researchers worldwide to prevent global health threats like antimicrobial resistance. The goal of the Global Nexus for Pandemics and Biological Threats is to ensure Canada and the world are better able to manage the […]
Aug-2020
Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, […]
Jun-2020
Hamilton’s Fusion Pharmaceuticals Inc. has increased its planned initial public offering on the Nasdaq by half and now hopes to raise up to US$230-million, the biotechnology developer said late Wednesday. The cancer drug developer filed Monday to go public, laying out plans to sell 8.35 million shares at US$14 to US$16 apiece, plus an option […]
Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). “We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and […]
Mar-2020
It doesn’t look that different from the other houses on Whitton Road in Westdale. Two-and-a-half storeys. A bay window. Some mock Tudor stylings. You might think a young family or a bunch of students live there. The smart home is part of a larger research effort by the McMaster Institute for Research on Aging (MIRA), […]
Triumvira Immunologics, Inc. (Triumvira), a Hamilton-based private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its novel T-cell therapy product TAC01-CD19 in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after at […]